Sanuwave Health (SNWV) Stock Price, News & Analysis

Company Overview

Sanuwave Health, Inc. is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S. Food and Drug Administration for treatment of chronic diabetic foot ulcers. This portable, hand-held device provides a convenient alternative to conventional wound-care methods by delivering precision acoustic pulses directly to the affected tissue, thereby promoting neovascularization and reducing healing times. Sanuwave also supplies disposable treatment cartridges and related consumables to healthcare providers, and has established distribution agreements in North America and select overseas markets to broaden patient access.

Headquartered in Alpharetta, Georgia, Sanuwave Health originated as Tissue Regeneration Systems, Inc. before adopting its current name to reflect an expanded focus on regenerative medicine technologies. Under the leadership of Chief Executive Officer Jeff Bean, the company continues to advance its clinical research programs, pursue regulatory clearances for additional indications, and explore strategic partnerships. Sanuwave’s ongoing mission is to deliver innovative, non-invasive therapeutic solutions that improve patient outcomes and reduce healthcare costs worldwide.

Key Stats

• Today's Range: $4.60 to $4.69
• 50-Day Range: $4.61 to $12.10
• 52-Week Range: $4.50 to $42.75
• Volume: 18,447 shs
• Average Volume: 91,959 shs
• Market Capitalization: $40.25 million
• P/E Ratio: 19.50
• Dividend Yield: N/A
• Price Target: $51.00
• Consensus Rating: Moderate Buy

Sanuwave Health Stock Analysis - MarketRank™

Sanuwave Health scored higher than 75% of companies evaluated by MarketBeat, and ranked 193rd out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Sanuwave Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Sanuwave Health has a consensus price target of $51.00, representing about 989.7% upside from its current price of $4.68.

Amount of Analyst Coverage

Sanuwave Health has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Sanuwave Health is 19.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.16.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sanuwave Health is 19.50, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.16.

Price to Book Value per Share Ratio

Sanuwave Health has a P/B Ratio of 14.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.14% of the float of Sanuwave Health has been sold short.

Short Interest Ratio / Days to Cover

Sanuwave Health has a short interest ratio ("days to cover") of 2.78, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sanuwave Health has recently decreased by 45.76%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sanuwave Health does not currently pay a dividend.

Dividend Growth

Sanuwave Health does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.43

News Sentiment

Sanuwave Health has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.97 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Sanuwave Health this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for SNWV on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sanuwave Health insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.40% of the stock of Sanuwave Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

42.53% of the stock of Sanuwave Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 8/30/2026
• Next Earnings (Estimated): 11/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:SNWV
• Previous Symbol: NASDAQ:SNWV
• CIK: 1417663
• Web: sanuwave.com
• Phone: (770) 419-7525
• Fax: 770-419-8634
• Employees: 40
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Sanuwave Health: $51.00
• High Price Target: $55.00
• Low Price Target: $47.00
• Potential Upside/Downside: +989.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.24
• Trailing P/E Ratio: 19.50
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $11.81 million
• Net Margins: 32.38%
• Pretax Margin: 34.73%
• Return on Equity: 1,728.10%
• Return on Assets: 39.04%

Debt

• Debt-to-Equity Ratio: 4.87
• Current Ratio: 1.28
• Quick Ratio: 0.89

Sales & Book Value

• Annual Sales: $44.05 million
• Price / Sales: 0.91
• Cash Flow: $1.70 per share
• Price / Cash Flow: 2.75
• Book Value: $0.32 per share
• Price / Book: 14.63

Miscellaneous

• Outstanding Shares: 8,600,000
• Free Float: 7,361,000
• Market Cap: $40.25 million
• Optionable: N/A
• Beta: 1.48